| Code | 1420E | ||||||||||
| MA number | 44/0170/22-S | ||||||||||
| Product Form: | tbl 120x250 mg (fľ.HDPE) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||||
| MAH, country: | Pharmevid s.r.o., Slovakia | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Container: | bottle HDPE | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 29.06.2022 |
| Validity: | 29.06.2027 |
| PIL: |
PIL_Abiraterone Pharmevid 250 mg tablety_08.2022.pdf
|
| SPC: |
SPC_Abiraterone Pharmevid 250 mg tablety_08.2022.pdf
|
| Safety feature | Yes |
| Data update: | 30.06.2022 |
